Answers are grounded in this paper and cite their sources.
Case reveals anemia and thrombocytopenia risks in triple-negative breast cancer, indicating TTP may emerge from PD-L1 therapy.
Thrombocytopenic purpura (TTP) is a hematologic emergency that may occur with PD‐L1 immunotherapy. New or worsening anemia and thrombocytopenia in patients started on PD‐L1 inhibitors should raise suspicion for TTP and prompt workup for thrombotic microangiopathy.
No takes yet. Share an insight, caveat, or question.
Ke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: